Literature DB >> 25502797

Childhood obesity, metabolic syndrome and Pentraxin-3.

P S N Menon1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25502797     DOI: 10.1007/s12098-014-1644-8

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  16 in total

Review 1.  Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop.

Authors:  George Alberti; Paul Zimmet; Jonathan Shaw; Zachary Bloomgarden; Francine Kaufman; Martin Silink
Journal:  Diabetes Care       Date:  2004-07       Impact factor: 19.112

2.  Plasma Pentraxin 3 as a biomarker of metabolic syndrome.

Authors:  Fatih Kardas; Leyla Akın; Selim Kurtoglu; Mustafa Kendirci; Zehra Kardas
Journal:  Indian J Pediatr       Date:  2014-07-29       Impact factor: 1.967

Review 3.  Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.

Authors:  K G M M Alberti; P Zimmet; J Shaw
Journal:  Diabet Med       Date:  2006-05       Impact factor: 4.359

Review 4.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

5.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

6.  Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome.

Authors:  Tsuneo Ogawa; Yurika Kawano; Takuroh Imamura; Kumiko Kawakita; Mina Sagara; Takeshi Matsuo; Yousuke Kakitsubata; Tadashi Ishikawa; Kazuo Kitamura; Kinta Hatakeyama; Yujiro Asada; Tatsuhiko Kodama
Journal:  Obesity (Silver Spring)       Date:  2010-01-28       Impact factor: 5.002

7.  Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?

Authors:  Michael P Stern; Ken Williams; Clicerio González-Villalpando; Kelly J Hunt; Steven M Haffner
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

8.  The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling.

Authors:  A Inforzato; S Jaillon; F Moalli; E Barbati; E Bonavita; B Bottazzi; A Mantovani; C Garlanda
Journal:  Tissue Antigens       Date:  2011-04

9.  Is pentraxin 3 involved in obesity-induced decrease in arterial distensibility?

Authors:  Asako Miyaki; Seiji Maeda; Mutsuko Yoshizawa; Maiko Misono; Hiroyuki Sasai; Nobutake Shimojo; Kiyoji Tanaka; Ryuichi Ajisaka
Journal:  J Atheroscler Thromb       Date:  2010-02-05       Impact factor: 4.928

10.  Obesity-induced inflammatory changes in adipose tissue.

Authors:  Kathryn E Wellen; Gokhan S Hotamisligil
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.